Citric acid 17.79g / Magnesium carbonate 11.57g effervescent powder sachets sugar free
Available from a pharmacy with pharmacist advice
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Citric acid + Magnesium carbonate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Citric acid + Magnesium carbonate on the MHRA register
Citramag effervescent powder sachets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 5 · 2005–2026
Showing the 50 most relevant studies, sorted by most relevant.
Nan Wang, Hong-fa Yu, Wanli Bi, et al.
Construction and Building Materials, 2018
Scribante A, Cosola S, Pascadopoli M, et al.
2025
The aim of this randomized clinical trial was to evaluate the efficacy of two different remineralising toothpastes in preventing dental caries and promoting oral health. Patients aged 6-18 years old with healthy and fully erupted first permanent molars (C1 and C2 DIAGNOdent scores) were enrolled and randomized into two groups according to the home-hydroxyapatite-based remineralising treatment used: the Trial group used zinc carbonate hydroxyapatite-based treatment (Biorepair Total Protective Repair), while the Control group used magnesium strontium carbonate hydroxyapatite conjugated with chitosan toothpaste (Curasept Biosmalto Caries Abrasion & Erosion). Dental and periodontal parameters were measured over a six-month period, including the DIAGNOdent Pen Index (primary outcome), BEWE Index, Plaque Index, Bleeding Score, Schiff Air Index, and ICDAS assessed with DIAGNOcam. A total of 40 patients were equally allocated in the two groups and finally analyzed. A significant reduction in the DIAGNOdent Pen score was reported in the Trial group after 1 month of treatment, while in the Control group, no significant change was found. The Trial group also showed a significant reduction in plaque levels after 3 months of treatment, while in the Control group, it occurred after 1 month. However, the Bleeding Score and Schiff Air Index showed no significant differences between the groups, suggesting that additional measures may be required to address gingival inflammation and hypersensitivity. The ICDAS index also showed no statistically significant changes, due to the limited duration of this study. Overall, zinc-hydroxyapatite-based toothpaste was more effective than magnesium strontium carbonate hydroxyapatite toothpaste in enhancing enamel remineralisation in the short-term period. The assigned treatments did not result in significant improvements in the oral indexes assessed in this study.
Abstract licence: CC BY
Attinger MC, von Felten S, Rodrigues CL, et al.
2025
- Magnesium Compounds
- Citric Acid
- Thyroxine
Gautam N. Mankaney, M. Ando, D. Dahdal, et al.
Therapeutic Advances in Gastroenterology, 2021
C. Cuffari, Steven L Ciciora, M. Ando, et al.
World Journal of Gastroenterology, 2020
Xin Ke, F. Zhang, Yan Zhou, et al.
Chemosphere, 2020
Gerzilov V, Hristakieva P
2025
- Poultry
- Acids
- Animal Feed
The poultry industry is continually exploring new feed additives to enhance poultry productivity and health. Since the European Union's (EU) 2006 ban on antibiotics as growth promoters, alternative methods have become essential to support health and growth in livestock production. In response, various strategies have been developed to replace nutritional antibiotics, aiming to combat antibiotic resistance and manage diseases that would otherwise require antibiotic intervention. One promising alternative is the incorporation of organic acids (OAs) and their salts as feed additives in poultry farming. OAs improve feed palatability, reduce pH levels in the gastrointestinal tract of birds, activate digestive enzymes, and inhibit the growth of pathogenic microorganisms while preserving beneficial microflora. These acids enhance metabolism, improve feed digestibility, and accelerate growth. Additionally, OAs support overall bird health, a key factor affecting productivity traits and, consequently, the economic performance and profitability of poultry farming. This article examines the potential applications of OAs in poultry nutrition.
Abstract licence: CC BY-NC
Xu Q, Chen D, Xiong J, et al.
2025
This review provides a comprehensive overview of the advancements in magnesium-based cementitious materials (MBCMs), including magnesium oxychloride cementitious material (MOC), magnesium oxysulfate cementitious material (MOS), and magnesium phosphate cementitious material (MPC). The hydration processes and products, performance characteristics, and applications in soil stabilization are systematically discussed. Key findings reveal that MOC exhibits rapid strength development and excellent thermal stability, while MOS demonstrates improved water resistance and mechanical properties. MPC is highlighted for its effectiveness in the immobilization of heavy metals. The environmental impact of MBCMs is also evaluated, highlighting their potential for sustainable development in civil engineering applications. The primary issues and challenges for MBCMs in soil curing include the insufficient stability of hydration products and inadequate understanding of curing mechanisms, leading to variable material properties and difficulties in precisely controlling the curing effects in practical engineering. Additionally, the complex composition of MBCMs and the highly variable characteristics of natural soils result in significant differences in curing effectiveness under different conditions, restricting their application scope and posing risks to project costs and quality stability.
Abstract licence: CC BY
Yu H, Zhang A, Cheng G, et al.
2026
Coral aggregate concrete (CAC) serves as a critical material for sustainable development in marine engineering, effectively addressing the shortage of aggregate resources in the construction of offshore islands and reefs. In this paper, the aggregate characteristics, static and dynamic mechanical properties and modification technology of CAC are systematically reviewed. Research indicates that the coral aggregates (CAs), due to its high porosity (approximately 50%), low bulk density (900-1100 kg/m3), and rough, porous surface, results in relatively low static compressive strength (20-40 MPa), insufficient elastic modulus, and significant brittleness in CAC. However, its dynamic performance shows the opposite advantage. Under impact loads, the energy absorption capacity is enhanced by 32.6-140.3%, compared to ordinary concrete (OC) due to the energy dissipation mechanism of pore platic deformation. Through the modification techniques, such as aggregate pre-treatment (acid washing/coating), incorporation of auxiliary cementitious materials (silica fume increases strength by 16.4%), fibre reinforcement (carbon fibres enhance flexural strength by 33.3%), and replacement with novel cementitious materials (magnesium sulphate cement improves chloride ion binding capacity by 90.7%), the mechanical properties and durability of CAC can be significantly optimised. This paper highlights gaps in current research regarding the high strain rate (>200 s-1) dynamic response, multi-factor coupled durability in marine environments, and the engineering application of alkali-activated materials, providing theoretical basis for future research directions.
Abstract licence: CC BY
Ferrante F, Battaglia G, Micale G, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.